^
Association details:
Biomarker:PD-L1 negative
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer

Published date:
12/28/2023
Excerpt:
We conducted a systematic review and meta-analysis to evaluate the benefit of adding immunotherapy to neoadjuvant chemotherapy in patients with localized NSCLC….The subgroup analyses demonstrated a consistent benefit with neoadjuvant immunotherapy independent of age, ECOG status, smoking status, and stage, while the benefit of neoadjuvant immunotherapy was lower in patients with PD-L1-negative tumors than patients with moderate or high levels of PD-L1 expression.
DOI:
https://doi.org/10.3390/cancers16010156